Cadila manufacturing facility in India gets FDA Form 483 for 5 observations

Cadila's Liva subsidiary was hit with a Form 483 by the FDA following an inspection of its plant in Vadodara, India. (FDA)

Liva Pharmaceuticals, a wholly owned manufacturing facility of Indian drugmaker Cadila Healthcare, was hit with a Form 483 (PDF) by the FDA following an inspection of its plant in Vadodara, India.

Regulatory inspectors visited the injectables plant from Aug. 20-28, during which they cited the company for five observations. Issues at the facility included problems with Liva’s product sterility procedures, deficiencies in monitoring environmental conditions, lack of proper training for employees and problems with its record keeping process.

In the Form 483, the agency said inspectors found “containers having obvious breach of container/closure integrity such as cracked container, broken container, containers with missing stopper/closures” that had not been rejected or discarded with appropriate documentation,

Free Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This webinar will discuss the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

“This was a product specific preapproval inspection,” the company said in a filing with the Bombay Stock Exchange. “It concluded with five observations. Liva will respond to the USFDA with 15 days.”

The company added that the Liva facility does not currently export any products to the U.S. market.

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.